Meeting
2017 ASCO Annual Meeting
Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).
Authors
Ibiayi Dagogo-Jack
Massachusetts General Hospital, Boston, MA
Ibiayi Dagogo-Jack , Fernando Santini , Juliana Eng , Beow Y. Yeap , Benjamin Izar , Emily Chin , Anya Litvak , David Randolph Jones , Mark G. Kris , Alice Tsang Shaw , Justin F. Gainor , Jamie E. Chaft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8536)
DOI
10.1200/JCO.2017.35.15_suppl.8536
Abstract #
8536
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
First Author: Benjamin J. Solomon
Poster
2013 ASCO Annual Meeting
BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).
First Author: Vassiliki Papadimitrakopoulou
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah
Poster
2023 ASCO Annual Meeting
Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.
First Author: Ross A. Soo